pDONR221-SLC3A2_STOP Citations (2)
Originally described in: The RESOLUTE consortium: unlocking SLC transporters for drug discovery.Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gurtl B, Klavins K, Klimek C, Lindinger S, Lineiro-Retes E, Muller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, ... Steppan CM Nat Rev Drug Discov. 2020 Jul;19(7):429-430. doi: 10.1038/d41573-020-00056-6. PubMed Journal
Articles Citing pDONR221-SLC3A2_STOP
| Articles |
|---|
| GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis. Cordova RA, Misra J, Amin PH, Klunk AJ, Damayanti NP, Carlson KR, Elmendorf AJ, Kim HG, Mirek ET, Elzey BD, Miller MJ, Dong XC, Cheng L, Anthony TG, Pili R, Wek RC, Staschke KA. Elife. 2022 Sep 15;11:e81083. doi: 10.7554/eLife.81083. PubMed |
| Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily. Digles D, Ingles-Prieto A, Dvorak V, Mocking TAM, Goldmann U, Garofoli A, Homan EJ, Di Silvio A, Azzollini L, Sassone F, Fogazza M, Barenz F, Pommereau A, Zuschlag Y, Ooms JF, Tranberg-Jensen J, Hansen JS, Stanka J, Sijben HJ, Batoulis H, Bender E, Martini R, IJzerman AP, Sauer DB, Heitman LH, Manolova V, Reinhardt J, Ehrmann A, Leippe P, Ecker GF, Huber KVM, Licher T, Scarabottolo L, Wiedmer T, Superti-Furga G. Front Pharmacol. 2024 Jul 9;15:1401599. doi: 10.3389/fphar.2024.1401599. eCollection 2024. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.